Several components of the clotting system are modified towards hypercoagulability in sickle cell disease (SCD). To date, hematopoietic stem cell transplantation (HSCT) is the only validated curative treatment of SCD. Here, we investigated the changes in the hemostatic potential of SCD children who've received a successful HSCT. Seventeen children with severe SCD were enrolled in the study. Thrombin generation (TG) was performed on citrated platelet-poor plasma, obtained before and 3, 6, 9, 12 and 15 months after HSCT. TG was triggered using 1 pM tissue factor and 4 µM phospholipids with or without thrombomodulin (TM). Before the HSCT, SCD children showed a higher endogenous thrombin potential (ETP), higher peak, higher velocity and shorter time-to-peak of TG than the normal controls (NC). ETP did not significantly change following the HSCT. However, the peak, velocity and time-to-peak of TG reversed to normal ranges from 3 months post-HSCT and remained so up to 15 months post-HSCT. The reduction of ETP after the addition of thrombomodulin (RETP) was dramatically reduced in SCD children before HSCT as compared with the NC. A partial reversal of RETP was observed from 3 months through 15 months post-HSCT. No statistical difference was observed for patient age or donor hemoglobinopathy status. In summary, successful HSCT improves the kinetics of TG but not the total thrombin capacity in SCD children.
Keywords: coagulation; hematopoietic stem cell transplantation; hemostatic potential; sickle cell disease; thrombin generation test.
Conflict of interest statement
The authors declare no conflict of interest.
Thrombin generation reveals high procoagulant potential in the plasma of sickle cell disease children.Am J Hematol. 2012 Feb;87(2):145-9. doi: 10.1002/ajh.22206. Epub 2011 Nov 4. Am J Hematol. 2012. PMID: 22052675
Evaluation of the procoagulant activity of endogenous phospholipids in the platelet-free plasma of children with sickle cell disease using functional assays.Thromb Res. 2012 Aug;130(2):259-64. doi: 10.1016/j.thromres.2011.10.016. Epub 2011 Nov 12. Thromb Res. 2012. PMID: 22079446
Thrombin generation in children with sickle cell disease: relationship with age, hemolysis, transcranial Doppler velocity, and hydroxyurea treatment.Eur J Haematol. 2013 Jul;91(1):46-54. doi: 10.1111/ejh.12113. Epub 2013 Apr 17. Eur J Haematol. 2013. PMID: 23530655
Curative Therapies for Sickle Cell Disease.Ochsner J. 2019 Summer;19(2):131-137. doi: 10.31486/toj.18.0044. Ochsner J. 2019. PMID: 31258425 Free PMC article. Review.
Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease.Blood Adv. 2018 Mar 13;2(5):575-585. doi: 10.1182/bloodadvances.2017012500. Blood Adv. 2018. PMID: 29535106 Free PMC article. Review.